Cargando…
The value measurement of emerging therapeutics in renal cell carcinoma: ASCO value framework and ESMO-MCBS
PURPOSE: Rapid development of novel therapeutics in renal cell carcinoma (RCC) has led to financial burden for patients and society. Value including clinical benefit, toxicity affecting quality of life and cost-effectiveness are a concern, prompting the need for tools to facilitate value assessment...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9275027/ https://www.ncbi.nlm.nih.gov/pubmed/35821026 http://dx.doi.org/10.1186/s12913-022-08279-6 |